Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: INCY stock price vs ROP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROP's multiple
Needs ROP P/E.
Implied fair value · at INCY's multiple
Needs INCY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: INCY FY 2025 (ended Dec 31, 2025) · ROP FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 4.62x · EV / EBITDA 13.50x
Capital structure 80% equity / 20% debt · EV / Revenue 6.33x · EV / EBITDA 15.86x
ROP carries the larger enterprise value at $49.99B against $23.73B; INCY trades on the lower EV / Revenue multiple (4.62x vs 6.33x); INCY on the lower EV / EBITDA (13.50x vs 15.86x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INCYTE CORPORATION · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ROPER TECHNOLOGIES, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.29x
0.50x
Net debt / EBITDA
Leverage against operating earnings
-0.90x
3.08x
Cash and equivalents
Liquid reserves on the balance sheet
$3.10B
$297.40M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
INCY vs AMGN
GILEAD SCIENCES, INC.
INCY vs GILD
VERTEX PHARMACEUTICALS INC / MA
INCY vs VRTX
REGENERON PHARMACEUTICALS, INC.
INCY vs REGN
BIOGEN INC.
INCY vs BIIB
HONEYWELL INTERNATIONAL INC
INCY vs HON
EMERSON ELECTRIC CO
INCY vs EMR
Fortive Corp
INCY vs FTV
Keysight Technologies, Inc.
INCY vs KEYS
METTLER TOLEDO INTERNATIONAL INC/
INCY vs MTD
Vontier Corp
INCY vs VNT
$1.51B
$10.01B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
